Bristol-Myers Squibb Company revenue by segment BMY

Annual Quarterly

Bristol-Myers Squibb Company splits its revenue into 20 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Growth Brands at $7.7 billion, 59% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	50,034	13,069	12,973	11,489	12,502	12,222	12,269	11,201	12,342
Growth Brands	—	7,662 share 58.6%	7,560 share 58.3%	—	—	—	—	—	6,363 share 51.6%
Legacy Brands	—	—	5,422 -4.4% share 41.8%	—	5,109 -14.6% share 40.9%	5,365 share 43.9%	5,673 share 46.2%	5,638 share 50.3%	5,979 share 48.4%
Eliquis	—	4,690 +25.2% share 35.9%	4,481 +21.8% share 34.5%	4,137 +16.0% share 36.0%	3,452 +8.0% share 27.6%	3,746 share 30.6%	3,680 share 30.0%	3,565 share 31.8%	3,195 share 25.9%
Other Growth Brands	—	731 share 5.6%	—	—	—	—	557 share 4.5%	—	—
Pomalyst Imnovid	—	—	—	513 share 4.5%	—	—	—	—	823 share 6.7%
Breyanzi	—	—	—	411 share 3.6%	—	—	—	—	—
Alliance And Other Revenues	—	—	—	—	391 share 3.1%	—	—	—	—
Opdivo Ovantig	—	—	261 +770.0% share 2.0%	—	133 share 1.1%	67 share 0.5%	30 share 0.2%	9 share 0.1%	—
Camzyos	—	—	—	—	—	—	260 share 2.1%	—	—
Other Revenues	—	—	—	—	—	—	241 share 2.0%	227 share 2.0%	—
Zeposia	—	—	169 share 1.3%	—	159 share 1.3%	161 share 1.3%	—	107 share 1.0%	—
Other Legacy Brands	—	154 share 1.2%	170 share 1.3%	156 share 1.4%	—	—	—	—	250 share 2.0%
Abecma	—	—	—	—	101 -3.8% share 0.8%	137 share 1.1%	—	—	105 share 0.9%
Sotyktu	—	100 +25.0% share 0.8%	87 +24.3% share 0.7%	69 +25.5% share 0.6%	85 +2.4% share 0.7%	80 share 0.7%	70 share 0.6%	55 share 0.5%	83 share 0.7%
Alliance Revenues	—	95 -24.0% share 0.7%	104 share 0.8%	94 +6.8% share 0.8%	115 -7.3% share 0.9%	125 share 1.0%	—	88 share 0.8%	124 share 1.0%
Sprycel	—	73 share 0.6%	88 -26.7% share 0.7%	73 -58.3% share 0.6%	80 -59.6% share 0.6%	—	120 share 1.0%	175 share 1.6%	198 share 1.6%
Krazati	—	—	55 +14.6% share 0.4%	50 +4.2% share 0.4%	56 +43.6% share 0.4%	53 share 0.4%	48 share 0.4%	48 share 0.4%	39 share 0.3%
Abraxane	—	—	55 -47.6% share 0.4%	50 -52.4% share 0.4%	84 -51.7% share 0.7%	74 share 0.6%	105 share 0.9%	105 share 0.9%	174 share 1.4%
Augtyro	—	—	—	—	—	—	—	—	15 share 0.1%
Other Revenue Hedging Activities	—	-7 share -0.1%	-9 share -0.1%	-15 share -0.1%	—	—	—	—	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: BMY (NYSE), CELG-RI (NYSE)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Princeton, NJ
SEC filer status: Large accelerated filer
SEC CIK: 14272

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.